MetrioPharm gains orphan drug status from EMA for MP1032
MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular…
Central Nervous System
-
-
Acumen and JCR partner on brain delivery therapy for Alzheimer’s
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery…
-
Illimis secures funding for GAIA-based Alzheimer’s therapeutics
Illimis Therapeutics has completed a Series B funding round, securing $42m to expedite the development of its Gas6-mediated Anti-Inflammatory Adaptor…
-
Niagen Bioscience signs exclusive licence deal for PD therapy
Niagen Bioscience has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital, Bergen, Norway, for the development of…
-
Eli Lilly receives FDA approval for Amyvid label update
The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid…
-
Novartis concludes Regulus Therapeutics acquisition
Novartis has completed its previously announced acquisition of US-based biopharmaceutical company Regulus Therapeutics for $1.7bn, strengthening its renal disease portfolio.…
-
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs
In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for…
-
Draig secures $140m for neuropsychiatric disorder therapies
Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies…
-
Supernus makes depression drug play with $795m Sage buyout
Fewer than five months after rejecting a takeover approach by Biogen, Sage Therapeutics has found a buyer in Supernus Pharmaceuticals.…
-
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
The US Food and Drug Administration (FDA) has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat…
